摘要
目的:研究慢性肺源性心脏病患者抗凝治疗前后抗凝血酶Ⅲ(AT-Ⅲ)和组织因子途径抑制物(TFPI)活性的变化。方法:60例慢性肺源性心脏病患者随机分为抗凝治疗组和常规治疗组,各30例,以及健康对照组60例,分别于治疗前后采集血样检测AT-Ⅲ、TFPI活性指标。结果:慢性肺源性心脏病患者的AT-Ⅲ活性明显低于健康对照组,而TFPI活性明显高于健康对照组,两组比较,有显著性差异(P<0.05);经低分子肝素钙抗凝治疗后,AT-Ⅲ活性明显升高,常规治疗组AT-Ⅲ活性变化不大,两组比较,有显著性差异(P<0.05),而TFPI活性在两组治疗前后变化均不大,无显著性差异。结论:AT-Ⅲ及TFPI活性测定是早期预测慢性肺源性心脏病血栓前期抗凝系统变化的客观指标,对凝血机制的病理生理学研究,以及指导临床合理选用抗凝药物有重要意义。
Objective： To study the changes of antithrombase m （AT-Ⅲ） and tissue factor pathway inhibitor （TFPI） activities in chronic cor pulmonale patients before and after anticoagulatory treatment. Methods： 60 cases of chronic cot pulmonale patients were divided into two groups, anticoagulatory treatment group and conventional treatment group, with 30 cases in each group, and 60 cases of people were selected as healthy control group. The blood samples of three groups were collected before and after treatment to determine the activities of AT-Ⅲ and TFPI. Results： The AT-1I activity of chronic cor pulmonale patients was significantly lower than healthy control group, while the TFPI activity was significantly higher than healthy control group （P〈0.05）. After low-molecular-weight heparin treatment, the AT-m activity was increased significantly, while there was no change in the conventional treatment group （P〈0.05）. There was no significant change in the activity of TFPI for both treatments. Conclusion： The AT-Ⅲ and TFPI activities are objective indicators for predicting changes in anticoagulant system in the prehrombosis phase of chronic cor pulmonale. It is also very important for the study of pathophysiology mechanism of coagulation, as well as for doctors to choose the fight anticoagulant.
出处
《中国医药导报》
CAS
2009年第20期11-12,共2页
China Medical Herald
基金
广东省深圳市龙岗区科学技术局医疗卫生项目(YM2007068)
